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Altered social-emotional functioning is considered to play an important role in the development
and maintenance of anorexia nervosa (AN). Recently, there has been increasing interest in inves-
tigating the role of intranasal oxytocin in social-emotional processing. The present study aimed
to investigate the effects of intranasal oxytocin on the interpretation and expression of emo-
tions among people with AN. Thirty women with AN and 29 age-matched healthy women took
part in the present study, which used a double-blind, placebo-controlled, cross-over design. The
participants received a single dose of 40 IU of intranasal oxytocin in one session and a placebo
spray in the other. Fifteen minutes after administration, the participants completed the Reading
the Mind in the Eyes Test to assess the interpretation of complex emotions and mental states
followed by a video task, which assessed expressions of facial affect when they were viewing
humorous and sad film clips. The intranasal oxytocin did not significantly influence the expres-
sion or interpretation of emotions in the AN or healthy comparison groups. The AN group
expressed significantly less positive emotion, spent more time looking away and reported experi-
encing a significantly more negative affect in response to the film clips. The finding that intra-
nasal oxytocin had little to no effect on the interpretation or expression of emotions in either
group supports the notion that the effects of oxytocin on social-emotional processing are not
straightforward and may depend on individual and environmental differences, as well as the
emotion being processed. Replication of these findings is necessary to explore the effect of tim-
ing on the effects of oxytocin before firm conclusions can be drawn. Nonetheless, these findings
add to the steady accumulation of evidence that people with AN have reduced emotional
expression and avoidance of emotionally provoking stimuli.
Key words: oxytocin, anorexia nervosa, social-emotional functioning, facial expressions, positive
affect, negative affect
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Current models of anorexia nervosa (AN) postulate that altered
social cognition and difficulties in social-emotional functioning
contribute to the development and maintenance of AN (1,2). Robust
evidence from recent meta-analyses shows that people with AN
have difficulties in a wide range of social-emotional domains,
including the accurate interpretation and appropriate expression of
emotions. Appropriate facial expression and mimicry increase proso-
cial behaviour and aid the accurate interpretation of emotions,
whereas an inappropriate or blunted expression of emotions has
been found to give rise to negative judgements and elicit a desire
for increased social distance (3–5). In eating disorders, it has been
suggested that problems in social communication contribute to the
maintenance of disordered eating by causing interpersonal difficul-
ties and increasing isolation (1,2). Thus, treatments targeting these
interpersonal problems may be beneficial for people with AN.
Behavioural studies have demonstrated that people with AN have
particular difficulties with accurately interpreting positive and nega-
tive emotions in faces, as well as tone of voice (6). People with AN
also have difficulties with accurately interpreting complex emotions
and mental states in tasks such as the Reading the Mind in the
Eyes Test (RMET) and other theory of mind tasks (6). Furthermore, a
recent meta-analysis showed that people with AN, depression and
autism display fewer positive and negative facial expressions when
viewing positive and negative emotional film clips (7). Interestingly,
people who have recovered from AN do not show similar difficul-
ties in the interpretation and expression of emotions (6–9). Thus,
these difficulties are possible secondary consequences of malnutri-
tion; however, the exact mechanisms underlying difficulties in
social-emotional processing in AN are still unclear.
The neuropeptide oxytocin is considered to pay a key role in
social-emotional functioning (10,11). A recent review has docu-
mented a range of abnormalities in oxytocin functioning in acute
AN (12). Additionally, another recent meta-analysis found that
people with AN have significantly lower peripheral endogenous oxy-
tocin levels than healthy individuals (13). Moreover, preliminary
proof of concept studies have found that a single dose of intrana-
sal oxytocin influences certain aspects of social-emotional process-
ing in eating disorders (14,15). Among people with AN, a single
dose of intranasal oxytocin attenuated attentional bias towards dis-
gusted faces (15), although it did not increase sensitivity to recog-
nise basic emotions, whereas, in people with bulimia nervosa and
healthy comparison (HC) participants, intranasal oxytocin increased
sensitivity to detect emotions (14). These mixed findings suggest
that further exploration of the effects of a single dose of intranasal
oxytocin on social-emotional functioning is still necessary.
A single dose of intranasal oxytocin has also been reported to
improve the interpretation of complex emotional states in a number
of different paradigms, including the RMET and the awareness of
social inference test, among healthy individuals (16–18). Addition-
ally, a single dose has been reported to further improve the inter-
pretation of complex emotions among those healthy individuals
who report difficulties in identifying and describing emotions (19).
Among clinical populations, a single dose of intranasal oxytocin has
been reported to improve the interpretation of complex emotions
among people with schizophrenia and depression, comprising disor-
ders characterised by difficulties in the interpretation of emotions
(16,20). Thus, these findings suggest that a single dose of intranasal
oxytocin may increase attention social-emotional cues particularly
among those individuals who have difficulties with such social-
emotional processes. However, to our knowledge, no studies to date
have investigated the effects of a single dose of intranasal oxytocin
on the interpretation of complex emotions in AN.
A single dose of intranasal oxytocin has also been found to
increase emotional empathy and cooperation among healthy indi-
viduals particularly when social information regarding the other
person was present (21,22). Additionally, recent studies have found
that a single dose of intranasal oxytocin can increase cooperation
and normalise the avoidant, flattened arousal responses to human
social sounds in autism spectrum disorder (23,24). Thus, oxytocin
may be a facilitator of social communication, including facial
expression of emotion. Few studies thus far have investigated the
effects of a single dose of oxytocin on emotion expression (25,26).
Among healthy populations, a single dose of intranasal oxytocin
has been reported to increase spontaneous facial mimicry in
response to emotionally provoking videos, as well as increase facial
expressivity during the instructed production of facial expressions
(25,26). Among clinical populations, a single dose of intranasal oxy-
tocin has been reported to increase facial expressivity in response
to emotionally provoking images among people with schizophrenia
and to reduce avoidant behaviours during a clinical interview in
people with borderline personality disorder (27,28). However, to our
knowledge, no studies to date have investigated the effects of
intranasal oxytocin on evoked emotional facial expressions and the
interpretation of complex emotions in AN.
The present study aimed to investigate the effects of a single
dose of intranasal oxytocin on the interpretation and expression of
emotions in people with AN and healthy control (HC) participants.
Based on the previous work outlined above, we hypothesised that
participants with AN would have anomalies in the interpretation
and expression of emotions and that oxytocin administration would
alleviate these anomalies. Additionally, we explored correlations
between oxytocin-induced changes in the interpretation and
expression of emotions and depression, autistic traits, and body
mass index (BMI) within the AN group. Finally, we also explored
differences in the interpretation and expression of emotions, as well
as the effects of oxytocin, between AN participants who were tak-
ing antidepressants during the study and those AN participants
who were free of psychotropic medication.
Materials and methods
Participants
Thirty women with AN were recruited to take part in the present study. The AN
participants were recruited through South London and Maudsley National
Health Service (NHS) Trust and eating disorder charity websites (BEAT https://
www.b-eat.co.uk/ and Succeed www.succeed-foundation.org). All interested
AN participants were included in the study if they were female, aged 16–
65 years, met the DSM-5 criteria for AN assessed with the Structured Clinical
Interview for DSM-5 (29) and did not meet any of the exclusion criteria for all
participants. Fifteen of the AN participants were receiving psychotropic medi-
cation during the study. Twenty-nine HC women were recruited to take part in
the study as a comparison group. The HC participants were recruited through
King’s College London circulars and notice boards in the local community. All
HC participants were screened for past and current psychiatric disorders with
the Structured Clinical Interview for DSM-5 (29) and excluded if they reported
any current or history of mental health difficulties or suicidality. Additionally,
participants were excluded if they met any of the overall exclusion criteria for
all participants, which included being pregnant, a history of (or current) alcohol
or drug abuse/misuse, hormonal disturbance not as a result of low weight
among the AN participants, current impairments in cardiovascular functioning,
and any regular medication excluding psychotropic medication among the AN
participants. Five HC participants reported taking the contraceptive pill and
were asked to take a break from the pill and wait for the onset of their next
menstrual cycle before taking part. Prior to taking part in the study, all partici-
pants provided their written, informed consent. The study was approved by the
National Health System Research Ethics Committee (14/LO/0128) and was con-
ducted in accordance with the Helsinki Declaration of 1975 (revised in 2008).
The sample size was based on an a priori power analysis conducted with
G*Power, which indicated that, altogether, 60 participants would be needed
to have sufficient statistical power (0.8) to detect significant effects (30).
© 2017 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
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Self-report measures
The Eating Disorder Examination Questionnaire (EDEQ) was used to obtain
an assessment of eating disorder psychopathology with the subscales:
restraint, eating concern, weight concern and shape concern (31). The relia-
bility of the EDEQ was high in the present study (Cronbach’s a = 0.98).
Assessments of depression, anxiety and stress were obtained using the
Depression, Anxiety and Stress Scale (DASS) (32). The reliability of the DASS
was high in the present study (Cronbach’s a = 0.98).
Autism Spectrum Quotient (AQ-10) is a short 10-item assessment of
autistic traits with high positive predictive value at clinical cut-off of 6 (33).
The reliability of the AQ-10 was acceptable in the present study (Cronbach’s
a = 0.70).
Design and procedure
The present study used a within subjects, placebo-controlled, double-blind
AB/BA cross-over design to explore the effects of intranasal oxytocin on
evoked facial expressions in AN. The study consisted of two sessions. In one
session, participants were asked to self-administer 10 puffs (five in each nos-
tril) of a nasal spray containing 40 IU of synthetic oxytocin (Syntocinon;
Novartis Pharmaceutical, Basel, Switzerland). In the other session, participants
were asked to self-administer 10 puffs (five in each nostril) of a placebo (pla-
cebo) nasal spray. The dose was based on previous work investigating the
effects of a single dose of intranasal oxytocin in eating disorders
(14,15,34,35). The placebo nasal spray was custom made to be identical to
the oxytocin spray minus the active ingredient. The order in which partici-
pants received oxytocin and placebo was counterbalanced and randomised.
All HCs, and AN participants if menstruating, were tested during the first 1–
10 days of the menstrual cycle. Additionally, the participants were asked not
to consume any food 2 h before the sessions and to refrain from smoking or
drinking alcoholic or caffeinated drinks 12 h before the sessions.
Fifteen minutes after administration, the participants were asked to com-
plete a computerised version of the RMET (36) presented with EPRIME, version
2.0 (Psychology Software Tools, Inc., Sharpsburg, PA, USA). The RMET con-
sists of a short practice trial and an experimental trial. In the practice trial,
participants were presented with 10 images of eyes and were asked to iden-
tify whether the eyes were male or female. In the experimental trial, partici-
pants are presented 36 pictures of eyes (18 male and 18 female) depicting
complex emotions. In this part of the task, participants are asked to identify
the emotion that the eyes are conveying by selecting one of four options
presented in each corner of the screen. The pictures were presented in a
randomised order in each session. In the present study, participants were
given infinite time to respond to each trial before moving onto the next.
Participants’ reaction times and accuracy were recorded.
Twenty-five minutes after administration, the participants were asked to
watch two short video clips, each lasting 2–2.5 min, during which they were
filmed. The two clips were chosen to evoke positive and negative emotions
in the participants. The first film clip (henceforth Film 1) was a humorous
scene from the film Four Weddings and a Funeral (1994), which has been
previously successfully been used in a number of studies to evoke positive
emotions (9,37–39). The second film clip (henceforth Film 2) was a sad
scene chosen from the film Shadowlands (1999), which has also been previ-
ously successfully used to evoke negative emotions in the studies listed
above (9,37–39). The same film clips were presented in both sessions in a
fixed order with a short clip of computer simulated waves presented before
each clip. This was performed to avoid carry-over effects from emotions
experienced before the task started, as well as to avoid carry-over effects
from the first film clip onto the second film clip.
After viewing each clip, participants were asked to rate how they were
feeling on the Positive and Negative Affect Schedule (PANAS) (40). The
PANAS consist of 20 emotion words and participants were asked to rate to
what extent they were experiencing each emotion on a scale of 1 (very
slightly or not at all) to 5 (extremely). The PANAS ratings were then anal-
ysed to establish participants self-reported positive and negative affect
scores in response to Film 1 and Film 2.
Noldus FACEREADER
Noldus FACEREADER (Noldus Information Technology BV, Wageningen, The
Netherlands) comprises facial expression analysis software that has been
developed to identify six basic emotions: happiness, sadness, fear, anger,
surprise and disgust. The software also detects neutral expressions. FACEREADER
reports the intensity to which each of the six basic emotions are expressed
in each frame on a scale of 0 to 1, where 0 indicates that the emotion is
not present and 1 indicates that the emotion is fully present. FACEREADER has
been validated using manual emotion coding systems and facial electromyo-
graphy (41–43). The present study focused on exploring expressions of hap-
piness and sadness.
Looking away
Looking away was analysed manually. The total number of seconds partici-
pants looked away from the film stimuli was recorded and analysed.
Statistical analysis
All data were analysed using STATA, version 14 (StataCorp, College Station,
TX, USA). Differences in clinical and demographic self-report measures
between the groups were analysed using a nonparametric median chi-
squared test.
As a result of the highly skewed nature of the data, the PANAS ratings
were transformed with square root transformation prior to analysis. Group
differences and effects of oxytocin/placebo on the expression of emotions,
PANAS ratings and looking away were explored with bootstrapped mixed
linear models with 1000 bootstrap replications. Drug (oxytocin, placebo),
Film (Film 1, Film 2), Group (AN, HC) and session (session 1, session 2) were
entered as fixed effects with a random intercept. Technical difficulties with
the video camera SD card led to loss of data from one AN participant and
three HC participants.
As described above, group differences and the effect of drug on the
interpretation of emotions on the RMET were examined using a boot-
strapped mixed linear model (1000 replications) with Drug (oxytocin, pla-
cebo), Group (AN, HC) and Session (session 1, session 2) entered as fixed
effects and a random intercept. As a result of the close proximity of the
sessions (1–5 days apart), we included Session as a fixed effect to control
for familiarity with the RMET and film stimuli. Significant interactions were
further explored by investigating post-hoc contrasts and pairwise compar-
isons. We additionally conducted further post-hoc analysis investigating the
effects of oxytocin on easy and difficult items between the two groups. We
used a median split to divide items into easy (accuracy > 75.42%) and diffi-
cult (accuracy < 75.42%) groups based on total sample accuracy. These
results are presented in the Supporting information (Doc S1, Table S2).
Additionally, we explored differences in the effects of intranasal oxytocin
between AN participants taking antidepressants during the time of the study
and those free of psychotropic medication in the above measures. As above,
the effects of drug on the interpretation and expression of emotions, PANAS
ratings and looking away were explored with similar 2 9 2 9 2 9 2 and
2 9 2 9 2 bootstrapped mixed linear models with 1000 bootstrap replica-
tions. The results are presented in the Supporting information (Doc. S1, Table
S3–S6, Figure S1–S2).
Within the AN group, relationships between oxytocin-induced changes in
the interpretation and expression of emotions, and depression (DASS:
© 2017 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
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depression subscale), autistic features (AQ-10) and BMI were analysed with
Spearman’s rho correlation. Prior to correlation analysis, oxytocin-induced
changes in the interpretation and expression of emotions were calculated by
subtracting the interpretation accuracy and facial expression scores in the
placebo condition from those in the oxytocin condition. Thus, positive scores
indicated greater accuracy and facial expressivity in the oxytocin condition,
whereas negative scores indicated greater accuracy and facial expressivity in
the placebo session. The results are presented in the Supporting information
(Doc S1, Table S6).
Results
Clinical and demographic characteristics
The clinical characteristics of the sample are presented in Table 1.
The AN and HC groups were matched for age. The AN group
had a significantly lower BMI than the HC group. Additionally,
the AN group a reported significantly higher incidence of eating
disorder psychopathology as measured on the EDEQ, and reported
higher restraint, eating concern, shape concern and weight con-
cern. Furthermore, the AN group scored higher on the DASS,
reporting more depression, anxiety and stress than the HC group.
Finally, there was a significant difference between the two groups
on level of education, with HC participants reporting a higher
level of education than the AN participants, 90% of whom
reported having taken time off from education as a result of
their illness.
There were no significant differences in age or BMI between
those AN participants taking antidepressants during the study and
those AN participants who were free of psychotropic medication
(Table 1). The medicated AN participants did report a higher
incidence of eating disorder symptomatology as measured on the
EDEQ, scoring higher on the eating concern, weight concern and
shape concern subscales than those free of medication. Addition-
ally, the medicated AN participants scored higher on the DASS,
Table 1. Clinical and Demographic Sample Characteristics.







non-medicated AN HC (n = 29) AN versus HC
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
v2,
P value Median (Q1, Q3)
v2,
P value
BMI 16.13 (14.56, 18.14) 17.63 (15.20, 18.51) 14.67 (14.37, 16.61) 2.13,
0.144
22.21 (20.78, 25.51) 35.55,
< 0.001
Age 24.50 (22.00, 28.25) 25.00 (22.00, 27.00) 24.00 (21.00, 29.00) 0.00,
1.000
25.00 (23.00, 27.50) 0.02,
0.875
Level of education 3.00 (1.00, 3.00) 3.00 (1.00, 3.00) 3.00 (1.00, 3.50) 0.00,
1.000
3.00 (3.00, 4.00) 12.34,
< 0.001
Time off education
as a result of
AN (years)
1.00 (0.69, 2.00) 1.50 (0.92, 2.50) 0.67 (0.25, 0.1.25) 2.17,
0.141
– –
EDEQ total 4.13 (3.00, 5.13) 4.49 (4.21, 5.50) 3.68 (2.66, 4.06) 19.27,
< 0.001
0.59 (0.34, 1.00) 35.27,
< 0.001
EDEQ restraint 3.70 (2.60, 5.05) 4.40 (2.60, 5.20) 3.40 (1.40, 4.80) 0.07,
0.796
0.60 (0.00, 1.70) 20.79,
< 0.001
EDEQ weight concern 4.20 (2.70, 5.65) 5.60 (3.80, 6.00) 3.00 (2.00, 4.60) 5.40,
0.020
0.60 (0.30, 1.40) 31.38,
< 0.001
EDEQ shape concern 4.86 (3.56, 5.91) 5.88 (5.38, 6.00) 4.25 (2.75, 4.75) 19.27,
< 0.001
0.75 (0.38, 1.38) 41.67,
< 0.001
EDEQ eating concern 4.10 (2.90, 4.80) 4.40 (3.20, 4.80) 3.6 (2.60, 4.40) 5.40,
0.020
0.20 (0.00, 0.40) 41.67,
< 0.001
DASS Total 63.00 (40.00, 86.00) 72.00 (54.00, 88.00) 46.00 (26.00, 86.00) 6.67,
0.010
4.00 (1.00, 10.00) 37.49,
< 0.001
DASS Depression 21.00 (13.50, 32.00) 30.00 (20.00, 40.00) 18.00 (10.00, 26.00) 6.67,
0.010
0.00 (0.00, 2.00) 26.61,
< 0.001
DASS Anxiety 12.00 (6.00, 21.00) 18.00 (10.00, 26.00) 8.00 (2.00, 20.00) 4.29,
0.038
0.00 (0.00, 2.00) 29.07,
< 0.001
DASS Stress 25.00 (17.50, 31.00) 26.00 (24.00, 30.00) 18.00 (14.00, 34.00) 0.27,
0.606
2.00 (0.00, 7.00) 37.49,
< 0.001
AQ 3.00 (4.00, 1.00) 2.00 (4.00, 1.00) 3.00 (4.00, 1.00) 0.17,
0.680
2.00 (3.00, 1.00) 1.38,
0.502
AN, anorexia nervosa; HC, healthy comparison; BMI, body mass index; EDEQ, Eating Disorder Examination Questionnaire; DASS, Depression, Anxiety and Stress
Scale; AQ, Autism quotient; Level of education: 1 = A-level/National Vocational Qualification, 2 = Diploma, 3 = Undergraduate degree, 4 = Postgraduate
degree.
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reporting more depression and anxiety but not stress than the non-
medicated AN participants (Table 1).
Performance on the RMET
Interpretation accuracy and reaction times (RT) in the AN and HC
groups following both oxytocin and placebo administration are pre-
sented in Fig. 1(A,B). The mixed model revealed a significant differ-
ence between groups, with the AN participants being significantly
more accurate than the HC participants (Table 2). There was also a
significant effect of session, with all participants being significantly
more accurate in session 2 than session 1 [Z = 2.39, P = 0.017,
95% confidence interval (CI) = 0.01–0.12]. There were no other sig-
nificant effects or interactions influencing accuracy.
In terms of RT, the mixed model revealed a significant effect of
session, with all participants responding faster in session 2 than
session 1 (Z = 3.86, P < 0.001, 95% CI = 1211.80 to 395.67).
There was also a significant Drug 9 Group 9 Session interaction
(Table 2). The interaction was first explored by investigating the
Drug 9 Group interaction within each session. The results revealed
that there was a significant Drug 9 Group interaction in session 2
(v2 = 12.53, P = 0.0004) but not in session 1 (v2 = 2.70,
P = 0.1006). The effect of drug was then investigated within each
group in session 2. The results revealed that oxytocin led to a sig-
nificantly slower RT in the AN group in (Z = 2.32, P = 0.020, 95%
CI = 157.26–1871.20) and a faster RT in the HC group in session 2
(Z = 2.62, P = 0.009, 95% CI = 2059.48 to 269.17).
We also explored the Group 9 Session within placebo and
oxytocin conditions. The post-hoc contrasts revealed a significant
Group 9 Session interaction following both placebo (v2 = 6.83,
P = 0.009) and oxytocin administration (v2 = 6.49, P = 0.011). The
pairwise comparisons revealed that HC participants were signifi-
cantly faster than the AN participants in session 2 (Z = 2.59,
P = 0.010, 95% CI = 1912.21 to 263.49) but not in session 1
(Z = 1.13, P = 0.259, 95% CI = 431.42 to 1602.88) following
oxytocin administration. Following placebo administration, the HC
participants were significantly slower than the AN participants in
session 2 (Z = 2.45, P = 0.014, 95% CI = 222.32–1986.10) but not
in session 1 (Z = 1.19, P = 0.235, 95% CI = 1293.64–317.61)
(Table 2).
Because 17 of the AN participants had completed the RMET
before, we also explored differences between the groups on task
performance without these participants to examine their impact.
These findings are presented in the Supporting information (Doc
S1). The results revealed that, although the AN participants were
still on average more accurate than the HC participants, this differ-
ence no longer reached significance (see Supporting information,
Table S1). As above, there was a significant effect of session sug-
gesting that participants were more accurate in session 1 than in
session 2.
Regarding RT, the results revealed a significant effect of ses-
sion, with all participants being faster in session 2, and a signifi-
cant Drug 9 Group interaction (see Supporting information,
Table S1). Further exploration of the interaction revealed that the
AN participants who had not completed the RMET before were
significantly slower in the oxytocin than placebo condition
(Z = 2.70, P = 0.007, 95% CI = 165.63–1045.27). A similar effect
was not present in the HC group (Z = 0.56, P = 0.576, 95%
CI = 503.51 to 280.00).
Expressions of happiness and sadness, and looking away
The intensity of expression of sadness and happiness in response to
Film 1 and Film 2 following placebo and oxytocin administration is
summarised for the AN and HC groups in Fig. 2(A,B) for Film 1 and
Fig. 2(C,D) for Film 2. The P-value was adjusted for multiple post-
hoc comparisons using the false discovery rate and was set at
P < 0.003 (44). As expected, the mixed model revealed a significant
effect of Film, with all participants across groups and sessions
expressing more happiness when viewing Film 1 than Film 2. The
results also revealed a significant effect of Group, with HC partici-
pants expressing more positive facial expressions than AN partici-
pants across films and sessions (Table 3). The model also revealed a
significant Film 9 Group and Drug 9 Film 9 Group 9 Session
interactions.
The Film 9 Group interaction was investigated further by explor-
ing the difference between the groups at the two levels of Film.
The post-hoc test revealed that the HC participants expressed sig-
nificantly more happiness than the AN participants when viewing




























Fig. 1. Percentage accuracy (A) and reaction times (B) on the Reading the Mind in the Eyes (RMET) in the anorexia nervosa (AN) and healthy comparison (HC)
groups in the oxytocin and placebo conditions. Grey dots represent individual data points; the box plot represents the median, interquartile range, and the
maximum and minimum of the data. RT, reaction time; ms, milliseconds.
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significant differences between the groups in expressions of happi-
ness when viewing Film 2 (Z = 1.34, P = 0.181, 95%
CI = 0.10–0.02).
The four-way interaction was first investigated by exploring the
Drug 9 Film 9 Group interaction within session 1 (v2 = 3.84,
P = 0.05) and session 2 (v2 = 1.02, P = 0.314), which did not yield
significant results. Next, the Drug 9 Film 9 Session interaction
was explored within the HC (v2 = 2.23, P = 0.135) and AN groups
(v2 = 1.85, P = 0.173), which did not yield significant results.
Finally, the Drug 9 Session 9 Group interaction was explored
within Film 1 (v2 = 4.06, P = 0.044) and Film 2 (v2 = 1.07,
P = 0.301), which also did not yield significant results. There were
no other significant effects or interactions influencing expressions
of happiness.
Regarding the expression of sadness, as above, the mixed model
revealed a significant effect of Film, with all participants across
Table 2. Performance on the Reading the Mind in the Eyes Test (RMET) in Anorexia Nervosa (AN) and Healthy Comparison (HC) Groups Following Oxytocin
and Placebo.
Drug AN (n = 30), mean  SD HC (n = 29), mean  SD v2, P value
Accuracy (%) Oxytocin 81.77  10.67 69.83  12.35 Drug: 0.27, 0.604
Session: 5.69, 0.017
Group: 31.25, < 0.001
Drug 9 Session: 2.86, 0.091
Drug 9 Group: 1.33, 0.250
Session 9 Group: 0.71, 0.400
Drug 9 Session 9 Group: 0.72, 0.397
Placebo 78.83  13.74 71.79  9.63
RT Oxytocin 5379.72  1802.67 5158.24  2671.37 Drug: 0.65, 0.420
Session: 14.90, < 0.001
Group: 0.01, 0.909
Drug 9 Session: 0.97, 0.324
Drug 9 Group: 1.84, 0.175
Session 9 Group: 0.01, 0.920
Drug 9 Session 9 Group: 11.31, 0.001
Placebo 4929.32  1600.89 5241.59  2282.45
RT, reaction time.
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Fig. 2. Intensity of expressions of sadness and happiness in response to Film 1 and Film 2 in the anorexia nervosa (AN) and healthy comparison (HC) groups
in oxytocin and placebo conditions. (A) Expressions of happiness in response Film 1, (B) expressions of sadness in response to Film 1, (C) expressions of happi-
ness in response to Film 2, (D) expressions of sadness in response to Film 2. Grey dots represent individual data points; the box plot represents the median,
interquartile range, and the maximum and minimum of the data. Film 1, humorous film clip; Film 2, sad film clip.
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groups and sessions expressing more sadness when viewing Film 2
than Film 1. There were no other significant effects or interactions
influencing expressions of sadness.
The total time (s) that participants looked away from the film stim-
uli is presented in Table 3. The mixed model revealed a significant
effect of group, with AN participants looking away more than HC par-
ticipants. There was also a significant effect of film and session, with
all participants spending more time looking away from Film 2 than
Film 1, and looking away more during session 2 than session 1. There
were no other significant effects or interactions (Table 3).
Subjective PANAS ratings
Ratings of subjective positive and negative affect following Film 1
and Film 2 in the AN and HC groups are presented in Table 4.
The P-value was adjusted for multiple post-hoc comparisons using
Table 3. Expressions of Happiness and Sadness, and Looking Away in Anorexia Nervosa (AN) and Healthy Comparison (HC) Groups During Film 1 and Film 2.
Film Drug AN (n = 30), mean  SD HC (n = 29), mean  SD v2, P value
Expressions of happiness Film 1 Oxytocin 0.15  0.16 0.27  0.18 Drug: 0.47, 0.494
Film: 134.66, < 0.001
Group: 5.81, 0.016
Session: 0.20, 0.592
Drug 9 Film: 0.12, 0.727
Drug 9 Group: 1.63, 0.202
Film 9 Group: 14.29, < 0.001
Drug 9 Session: 0.05, 0.818
Film 9 Session: 2.08, 0.149
Group 9 Session: 1.11, 0.293
Drug 9 Film 9 Group: 0.29, 0.592
Drug 9 Film 9 Session: 0.03, 0.857
Drug 9 Group 9 Session: 0.94, 0.857
Film 9 Group 9 Session: 0.01, 0.905
Drug 9 Film 9 Group 9 Session: 4.07, 0.044
Placebo 0.16  0.17 0.22  0.16
Film 2 Oxytocin 0.05  0.09 0.03  0.04
Placebo 0.05  0.10 0.02  0.03




Drug 9 Film: 0.76, 0.384
Drug 9 Group: 0.73, 0.392
Film 9 Group: 1.30, 0.254
Drug 9 Session: 0.06, 0.801
Film 9 Session: 0.57, 0.451
Group 9 Session: 0.34, 0.559
Drug 9 Film 9 Group: 1.13, 0.289
Drug 9 Film 9 Session: 0.64, 0.422
Drug 9 Group 9 Session: 0.71, 0.398
Film 9 Group 9 Session: 0.23, 0.631
Drug 9 Film 9 Group 9 Session: 0.48, 0.488
Placebo 0.004  0.006 0.02  0.07
Film 2 Oxytocin 0.01  0.01 0.01  0.02
Placebo 0.03  0.05 0.03  0.08
Looking away (s) Film 1 Oxytocin 1.28  2.49 0.23  0.51 Drug: < 0.01, 0.948
Film: 8.58, 0.003
Group: 18.05, < 0.001
Session: 7.97, 0.005
Drug 9 Film: 0.07, 0.797
Drug 9 Group: 0.72, 0.397
Film 9 Group: 1.87, 0.172
Drug 9 Session: 3.11, 0.078
Film 9 Session: 0.09, 0.762
Group 9 Session: 3.31, 0.069
Drug 9 Film 9 Group: 0.12, 0.728
Drug 9 Film 9 Session: 0.09, 0.767
Drug 9 Group 9 Session: 1.98, 0.160
Film 9 Group 9 Session: 0.04, 0.841
Drug 9 Film 9 Group 9 Session: 2.59, 0.107
Placebo 1.00  1.93 0.31  0.74
Film 2 Oxytocin 2.72  3.72 0.65  2.08
Placebo 2.38  4.69 1.08  2.35
Film 1, humorous film clip; Film 2, sad film clip.
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the false discovery rate and was set at P < 0.004 (44). The mixed
model exploring ratings of positive affect on the PANAS revealed
a significant effect of group in ratings of positive affect, with the
HC participants reporting a more subjective positive affect relative
to the AN participants (Table 4). There was also a significant
effect of Film, with all participants reporting more positive affects
following Film 1 than Film 2, and a significant effect of session,
with participants reporting a more positive affect in session 1
than session 2.
The mixed model exploring ratings of subjective positive affect
also revealed significant Film 9 Session and Drug 9 Film 9 Ses-
sion interactions (Table 4). The three-way interaction was first
explored by investigating the Drug 9 Film interaction in session 1
and session 2, which revealed no significant interactions (session 1:
v2 = 2.53, P = 0.112; session 2: v2 = 4.04, P = 0.044). The three-
way interaction was then explored by investigating the Ses-
sion 9 Drug interaction in the two levels of film, which revealed
no significant interactions (Film 1: v2 = 5.24, P = 0.023; Film 2:
v2 = 1.34, P = 0.247). Finally, the three-way interaction was
explored by investigating the Film 9 Session interaction at the
two levels of drug, which revealed a significant interaction in the
oxytocin (v2 = 11.19, P = 0.001) but not placebo session
(v2 < 0.01, P = 0.980). Further pairwise comparison revealed that
participants who received oxytocin in the first session and those
who received it in the second session reported a more subjective
positive affect in response to Film 1 than Film 2 (session 1;
Z = 7.55, P < 0.001, 95% CI = 11.42 to 6.71; session 2:
Z = 2.16, P = 0.031, 95% CI = 5.00 to 0.24). There was
also a significant Group 9 Session interaction (Table 4), with HC
participants reporting a significantly more positive affect in ses-
sion 1 than 2 (Z = 3.84, P < 0.001, 95% CI = 4.21 to
1.36). There was no significant differences between the session
within the AN group (Z = 0.84, P = 0.399, 95% CI = 2.14 to
0.86).
The mixed model exploring ratings of negative affect revealed a
significant effect of Film, with all participants reporting significantly
more negative affect in response to Film 2 than Film 1. There was
also a significant difference between groups in ratings of negative
affect, with AN participants reporting a more negative affect than
the HC participants (Table 4).
Table 4. Positive and Negative Affect Schedule (PANAS) Rating Following Film 1 and Film 2 in Anorexia Nervosa (AN) and Healthy Comparison (HC) Groups.
PANAS Film Drug AN (n = 30), mean  SD HC (n = 29), mean  SD v2, P value
Positive affect Film 1 Oxytocin 11.00  4.67 14.36  7.16 Drug: 1.30, 0.254
Film: 131.20, < 0.001
Group: 58.09,< 0.001
Session: 10.66, 0.001
Drug 9 Film: 0.05, 0.829
Drug 9 Group: 0.29, 0.587
Film 9 Group: 0.02, 0.879
Drug 9 Session: 1.09, 0.297
Film 9 Session: 6.38, 0.012
Group 9 Session: 4.10, 0.043
Drug 9 Film 9 Group: 0.07, 0.789
Drug 9 Film 9 Session: 4.54, 0.032
Drug 9 Group 9 Session: 0.02, 0.882
Film 9 Group 9 Session: 2.53, 0.111
Drug 9 Film 9 Group 9 Session: 0.43, 0.512
Placebo 11.72  5.71 15.84  6.04
Film 2 Oxytocin 5.21  4.29 8.72  7.27
Placebo 5.57  4.61 9.60  6.51
Negative affect Film 1 Oxytocin 5.07  6.08 0.88  1.69 Drug: 0.64, 0.425
Film: 33.10, < 0.001
Group: 69.99, < 0.001
Session: 0.05, 0.824
Drug 9 Film: < 0.01, 0.950
Drug 9 Group: 0.05, 0.820
Film 9 Group: 1.32, 0.251
Drug 9 Session: 1.14, 0.285
Film 9 Session: 0.29, 0.592
Group 9 Session: 0.41, 0.521
Drug 9 Film 9 Group: 0.28, 0.599
Drug 9 Film 9 Session: 0.10, 0.750
Drug 9 Group 9 Session: 1.54, 0.215
Film 9 Group 9 Session: 0.03, 0.872
Drug 9 Film 9 Group 9 Session: 0.18, 0.673
Placebo 4.28  4.57 0.88  1.45
Film 2 Oxytocin 8.82  6.78 3.68  5.37
Placebo 8.57  5.49 3.08  3.30
Film 1, humorous film clip; Film 2, sad film clip.
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Discussion
The present study aimed to investigate the effects of a single dose
of intranasal oxytocin on the interpretation and expression of emo-
tions in people with AN and HC participants. By contrast to what
was hypothesised based on the previous literature, oxytocin admin-
istration did not have a significant impact on the interpretation or
expression of emotions in either group. However, as hypothesised,
the present findings replicated previous work demonstrating
that, relative to HC, people with AN display a less positive facial
affect, spend more time looking away from the emotional stimuli,
and report a less subjective positive affect when viewing emotional
film stimuli. Surprisingly, the AN participants were significantly
more accurate with respect to interpreting complex emotions in the
RMET than the HC participants. Finally, we found that AN partici-
pants who were taking antidepressants during the study expressed
a less positive facial affect when viewing the humorous film and
were less accurate with respect to interpreting complex emotions
relative to non-medicated AN participants.
By contrast to what was hypothesised, we did not find signifi-
cant effects of intranasal oxytocin on the expression of facial
affect. These findings were somewhat surprising considering that
previous studies have reported a significant effect of oxytocin on
expression of emotions among healthy and clinical populations
(25–27). The discrepancy could arise from the fact that previous
studies have largely utilised different kinds of emotionally
provoking stimuli, including threatening social and nonsocial stimuli
(25–27). Indeed, Korb and Malsert (25) found no changes in the
expression of facial affect in response to positive facial expressions,
although they did find changes in frowning in response to angry
faces. Furthermore, intranasal oxytocin may differentially influence
spontaneous facial expression, instructed production of facial
expression (26) and facial mimicry during an emotion identification
task (25). However, in a recent meta-analysis and systematic review
conducted by our group, we found that oxytocin did not have a
significant effect on emotion expression (J. Leppanen, K. W. Ng, K.
Tchanturia and J. Treasure, unpublished data).
Additionally, we found no significant effects of oxytocin adminis-
tration on the accuracy of complex emotion interpretation in the
AN or HC groups. In part, these findings support a recent proof of
concept study, which found that intranasal oxytocin did not
improve sensitivity to recognise basic emotions in AN (14). How-
ever, the previous study used a different task to assess interpreta-
tion of emotions and found that intranasal oxytocin improved
emotion recognition sensitivity in HC participants and people with
bulimia nervosa (14). Similarly, other previous studies have reported
that a single dose of intranasal oxytocin significantly improved
recognition of complex emotions on the RMET among healthy indi-
viduals (17,18). However, recently, there have also been some failed
replications of these findings suggesting that the effects of intrana-
sal oxytocin on social-emotional processing are likely to more com-
plex than previously anticipated (45–47). Furthermore, in our recent
meta-analysis and systematic review, we found that, when fourteen
previous studies were pooled together, a single dose on intranasal
oxytocin did not have a significant impact on any theory of mind
measures, including RMET (J. Leppanen, K. W. Ng, K. Tchanturia and
J. Treasure, unpublished data). However, in a simpler test of recog-
nition of basic emotions, a single dose of oxytocin improved recog-
nition of fear and increased sensitivity to recognise anger in
healthy individuals only (J. Leppanen, K. W. Ng, K. Tchanturia and J.
Treasure, unpublished data).
Indeed, a systematic review has reported that almost half of
studies investigating the effects of intranasal oxytocin on social-
emotional processing did not report significant effects of oxytocin.
Furthermore, where significant effects were found, 63% of the time,
the effects were moderated by environmental factors or individual
differences (10). Additionally, a more recent systematic review has
suggested that the varied effects of oxytocin on social-emotional
processing may be moderated by social boundaries, such that
oxytocin not only increases social-affiliative behaviour within an
‘in-group’, but also increases distrust and desire to punish strangers
and ‘out-group’ members (48). This notion is supported by a recent
study reporting that oxytocin-induced noncooperation in the pris-
oner’s dilemma, a trust game, was influenced by fear (49). It was
suggested that oxytocin may have increased sensitivity fear-indu-
cing social stimuli leading to noncooperation (49). Thus, it may be
that the previously seen effects of oxytocin on social-emotional
processing are a by-product of its effects on feelings of belonging-
ness. Further exploration of the effects of oxytocin on expression of
emotions in different social boundary conditions may be of interest
with respect to evaluating its therapeutic potential.
When viewing the humorous film clip, the AN participants
expressed significantly less positive facial affect than the HC partic-
ipants, although there were no significant differences between the
groups when viewing the sad film clip. Relative to the HC group,
the AN participants also spend more time looking away from both
emotional film clips, and reported experiencing a less positive affect
and a more negative affect in response to the humorous and sad
film clips. The present findings add to the steady accumulation of
evidence indicating that the AN group has difficulties expressing
positive emotions and also has a tendency to avoid emotional stim-
uli (7,37–39,50). Furthermore, previous studies have shown that,
relative to HC women, adolescents and adult women with AN do
not display more negative facial expressions in response to negative
film stimuli despite reporting a more negative affect (38,51). Taken
together, these findings suggest that there may be a general dis-
connect between subjective experience and external display of emo-
tions and a tendency to avoid emotional engagement. Such
difficulties have important affective and social consequences (4,52)
and are thus important targets for interventions.
By contrast to what we expected, AN participants were signifi-
cantly more accurate than the HC participants with respect to
interpreting complex emotions in the RMET. This finding is in direct
contrast with previous work showing that AN participants have dif-
ficulties with accurately interpreting complex emotions in the RMET
(53–55). However, upon closer inspection, on average, the AN par-
ticipants in the present study did not appear to outperform those
in some previous studies (53,55). The HC participants, on the other
hand, were less accurate than those in previous case–control stud-
ies and large sample validation studies (53–57). Although, it is
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difficult to know what led to these unexpected findings, it is unli-
kely to be a result of the HC group having general difficulties with
understanding the task. Had that been the case, we would have
expected there to be significant differences between the groups in
accuracy and response times, which did not occur in the present
study. Additionally, the majority of the AN participants (57%) were
more familiar with the RMET than HC participants, having com-
pleted it before as part of other studies, and some of them per-
formed unexpectedly well on the task, with accuracy percentages
of up to 100%. Indeed, once these participants were removed, the
differences between the AN and HC groups did not reach signifi-
cance. However, there still remained a small difference between the
groups, with AN participants being more accurate.
Interestingly, we also found significant differences in accuracy
and reaction times between sessions 1 and 2 on the RMET across
groups, with all participants becoming more accurate and faster in
session 2 even though no feedback on performance was given.
These findings appear surprising considering that previous test–ret-
est reliability studies have found no such effects in the RMET
among healthy populations (58,59). However, it is of note that, in
these studies, a minimum of 2 weeks fell between the first admin-
istration of the task and the retest (58,59), whereas, in the present
study, the two sessions were only 1–5 days apart. Other studies
that have used shorter intervals between test and retest, ranging
from 1 h to 1 week, have found improvements in accuracy and
response times in a range of social-emotional tasks (60,61). Fur-
thermore, a few studies have found implicit learning effects over
the course an emotion recognition task in healthy and other clinical
populations, including people with depression and borderline per-
sonality disorder (62,63). Therefore, it is possible that, because the
two sessions in the present study were so close, participants
became familiarised with the stimuli, leading to a significant
improvement in task performance.
The present study also explored differences between participants
taking antidepressants and those free of psychotropic medication.
As might be expected, those taking antidepressants reported signif-
icantly more eating disorder psychopathology, depression and anxi-
ety than those free of psychotropic medication, suggesting that
medicated AN participants were more severe. However, when these
confounding factors were accounted for, the medicated AN partici-
pants remained significantly less accurate with respect to interpret-
ing emotions, and were less expressive and reported a less positive
affect when watching the humorous Film 1 than the non-medi-
cated AN group. Although, it is possible that additional con-
founders were not accounted for, a recent study investigating
facial expressivity among people with AN also reported a reduced
expression of positive facial affect among AN participants taking
antidepressants (9). Further exploration of the effects of antide-
pressants on social-emotional processing in people with acute AN
may be of interest.
Clinical implications
The present findings add further evidence to the wealth of research
suggesting that people with AN may have a general disconnect
between subjective experience and expression of emotions (38,51).
Appropriate expression of emotions is one of the corner stones of
social interaction and a blunted facial affect can have profound
affective and social consequences (4,52). Behavioural studies have
found that inhibiting the expression of facial affect in response to
emotionally provoking stimuli is associated with increases in blood
pressure and reductions in subjective enjoyment (52,64). Additionally,
when viewing videos of people displaying either appropriate, inappro-
priate or blunted reactions to emotional stimuli, participants rated
those people who displayed a blunted response to positive emotional
stimuli more negatively and expressed a greater desire for increased
social distance from these individuals (4). Thus, these problems with
social communication may contribute to the elevated negative mood,
isolation and loneliness that are common features of AN (65).
Limitations
The main limitation of the present study was the relatively short
interval between the administration of oxytocin and the first task.
However, there are previous studies that have used a similar short
interval between administration and the task and have reported
significant differences in social-emotional processing between oxy-
tocin and placebo sessions (66). However, it is not possible to
determine whether the lack of oxytocin-induced effects in the
RMET in the present study was not at least partly a result of this
short interval. Still, previous work investigating the temporal profile
of another neuropeptide similar to oxytocin (i.e. vasopressin) has
found that significant effects occur within 10 min of administration
(67). Nonetheless, replication of the present findings with a longer
interval between administration and tasks is necessary.
Although the sad film has been successfully used in many previ-
ous studies (37–39), in the present study, we found that the major-
ity of the participants were not familiar with the film Shadowlands
(1999) and did not understand it. Thus, most of the participants
were not sufficiently affected by the film and did not express a
sufficient negative facial affect to be detected by FACEREADER, which
provides a mean valence score for the duration of the film. If par-
ticipants expressed a negative facial affect on only couple of occa-
sions during the film but were otherwise neutral during the
majority of the film, those short expressions would be averaged out
in the mean valence score. A previous study used clips from differ-
ent films tailored specifically for younger participants and found
robust results showing reduced facial expressivity in young people
with AN when viewing both happy and sad film clips (51). Future
research may benefit from tailoring the clips for the participant
group to ensure they are sufficiently familiar with the story to
engage with the clips.
Compared to previous work (37,38,53,54), the present study
employed a modified procedure in which the experimenter stayed
in the room during all tasks. Although this allowed the experi-
menter to tackle some practical difficulties (e.g. a participant mov-
ing outside of camera range or watching the clips in a different
order), it may have led the participants to feel less able to engage
and become involved with the film clips during the film task. Future
© 2017 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
on behalf of British Society for Neuroendocrinology.
Journal of Neuroendocrinology, 2017, 29, 10.1111/jne.12458
10 of 13 J. Leppanen et al.
studies may benefit from finding alternative ways to combat non-
compliance, at the same time as giving participants sufficient pri-
vacy to engage with the films.
Finally, the present study did not assess participants IQ, which
can impact task performance. This is a limitation when comparing
the performance of the two groups on the RMET, which requires
an understanding of adjectives describing complex emotions.
Although this did not directly impact the investigation of the
effects of oxytocin in the cross-over study, future work should con-
duct a full IQ assessment when attempting to compare the perfor-
mance of two or more groups on a similar neuropsychological test.
Conclusions
The present study aimed to investigate the effects of a single dose of
intranasal oxytocin on difficulties in the interpretation and expression
of emotions in AN. The findings revealed that oxytocin did not signifi-
cantly influence the interpretation of complex emotions or facial
expressivity in response to positive or sad emotional stimuli in AN.
These findings are supported by recent work showing that intranasal
oxytocin does not improve emotion recognition sensitivity in people
with AN and selectively improves the expression of negative emotions
in response to threatening stimuli (14,25–27). However, replication of
these findings with different intervals between oxytocin administra-
tion and the task is necessary before firm conclusions can be drawn.
Taken together, these findings suggest that there may be anomalies
present in social-emotional processing in people with AN that are not
resolved with a single dose of intranasal oxytocin.
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